FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers

World News: . []

SAN DIEGO and TORONTO June 29 2018 GLOBE NEWSWIRE -- Aptose Biosciences Inc NASDAQAPTO TSXAPS today announced that the US Food and Drug Administration FDA has notified the company that it has lifted the clinical hold on APTO-253 Ap tose’...

More news and information about Aptose Biosciences, Inc.

Published By:

Globe Newswire: 12:00 GMT Friday 29th June 2018

Published: .

Search for other references to "lifts" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us